Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
Clinical trial NCT07482670 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07482670
- Sponsor
- Xiangya Hospital of Central South University
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-03-02
- Primary completion
- 2027-12-31
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.